A Silicon Valley startup just cracked the code on psychedelic medicine's biggest problem. Mindstate Design Labs has created what CEO Dillan DiNardo calls "the least psychedelic psychedelic that's psychoactive" - a drug that delivers therapeutic benefits without the mind-bending trip. Backed by OpenAI founders and other tech heavyweights, the company's AI platform successfully engineered its first compound to pass Phase I trials with zero hallucinations.
Mindstate Design Labs just proved that you can have your psychedelic cake and eat it too - minus the potentially terrifying trip that comes with traditional compounds. The startup's first drug candidate, MSD-001, sailed through Phase I trials with results that could reshape mental health treatment.
The numbers tell the story. In trials conducted at the Centre for Human Drug Research in the Netherlands, 47 healthy participants took five different doses of the company's engineered compound. Every single person experienced psychoactive effects within 30 minutes, with peak intensity hitting around 90 minutes. But here's the kicker - zero hallucinations, zero self-disintegration, zero of the overwhelming experiences that make traditional psychedelics so intimidating for many patients.
"We created the least psychedelic psychedelic that's psychoactive," CEO Dillan DiNardo told WIRED. "It is quite psychoactive, but there are no hallucinations." That's not marketing speak - brain imaging data confirmed the compound produced the same neural patterns as psilocybin and other first-generation psychedelics, just without the mental fireworks.
The breakthrough stems from Mindstate's unique AI approach to drug discovery. Founded in 2021 with backing from Y Combinator and the founders of OpenAI, Neuralink, Instacart, Coinbase, and Twitch, the company built AI models that digest biochemical data from psychoactive drugs alongside more than 70,000 "trip reports" scraped from clinical trials, drug forums, Reddit, and even the dark web.
This massive dataset allowed Mindstate to reverse-engineer what makes psychedelics tick. Their analysis revealed that MSD-001, a proprietary formulation of 5-MeO-MiPT (street name "moxy"), targets the brain's serotonin 2a receptor without the messy multi-site interactions that cause classic psychedelic chaos.
"The thesis was, if we essentially stripped out all of those other biochemical interactions, we'd be left with a drug that was quite tofu-like by psychedelic standards," DiNardo explained. Participants reported heightened emotions, enhanced imagination, and brighter colors - but maintained full awareness and control throughout their experience.
The implications are huge for patients currently locked out of psychedelic therapy. Alan Davis, director of the Center for Psychedelic Drug Research at Ohio State University, sees potential for treating individuals with psychotic disorders, personality disorders, and other conditions where traditional psychedelics are too risky. "These findings suggest that a mild psychedelic experience, one without hallucinations, could make for a safe and potentially therapeutic experience," Davis told WIRED.
Mindstate's timing couldn't be better. The FDA's rejection of MDMA-assisted therapy last year highlighted the regulatory challenges facing traditional psychedelic treatments, particularly around the complex talk therapy components. DiNardo expects Mindstate's approach to sidestep these hurdles by focusing purely on the drug's effects, similar to how Spravato (ketamine) is administered under medical supervision without extensive therapy integration.
The company isn't stopping with MSD-001. DiNardo describes their compound as "psychedelic tofu" - a neutral base that can be combined with other drugs to achieve precise mental states. Their next target combines the base compound with other molecules to reduce anxiety, increase insight, and enhance aesthetic perception, potentially treating mood disorders, compulsive behaviors, and phobias.
Not everyone's convinced this approach captures the full value of psychedelics. Rachel Yehuda, director of the Parsons Research Center for Psychedelic Healing at Mount Sinai, argues that "psychedelics are valuable because of their richness, their unpredictability, and the depth that comes from engaging with unconscious material." She doesn't consider Mindstate's compound a true psychedelic.
But for the millions suffering from depression and anxiety who just want relief without existential upheaval, Mindstate's "least psychedelic psychedelic" could be exactly what they need. As Yehuda acknowledges, "A lot of people who are suffering from depression and anxiety just want to feel better. And that's OK."
Mindstate's success represents more than just another biotech milestone - it's proof that AI can solve medicine's most complex challenges by finding entirely new approaches. By stripping away psychedelics' scariest side effects while preserving their therapeutic potential, the company has opened a path for millions of patients who couldn't access these treatments before. Whether this "psychedelic tofu" approach captures the full healing power of traditional compounds remains to be seen, but for an industry desperate for safer alternatives, Mindstate just delivered exactly what the doctor ordered.
